Chantix, manufactured by Pfizer, is an anti-smoking medication that has been linked to many serious, life-threatening side effects. In 2008, the FDA required Pfizer to update the warnings with a “Black Box” regarding the risk of suicide, attempted suicide, self-mutilation and self-harm, and death. Recently, researchers have also linked Chantix to an increased risk of heart attack, stroke, and death.
UPDATE: Pfizer Loses Bid to Remove Chantix Black Box Warning
October 17, 2014 — Eleven members of an FDA advisory panel have rejected Pfizer’s bid to remove a “Black Box” warning about suicide and psychiatric events from the label on Chantix, an anti-smoking medication. Click here to read more.
December 12, 2012 — The FDA has published a Safety Communication to warn about a potential increased risk of heart attack, stroke, and death associated with Chantix. Click here to read more.
What is the problem with Chantix?
Chantix was approved by the FDA in 2006 as a smoking cessation medication. Chantix works by blocking the effect that nicotine has on the brain. This reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. It was designed to work in conjunction with behavior modification therapy to help people work through their tobacco addiction. In November 2007, the FDA issued an early communication regarding reports of suicide and severe suicidal thoughts which have been associated with Chantix. Doctors we unfortunately not warned by Pfizer of these severe side effects. In July 2011 and December 2012, the FDA again updated the label to warn about a possible increased risk of heart attack, stroke, and death.
Side Effects of Chantix
There are a variety of side effects associated with Chantix. Our firm is pursing the following types of serious, life-threatening side effects:
- Heart problems
- Heart attack
- Violent Behavior
- Attempted Suicide
- Self-Mutilation and Self-Harm
Chantix Class Action Lawsuit Information
Pfizer Inc. has faced over 3,000 lawsuits involving Chantix. These lawsuits were not centralized in a class action — instead, they were individual lawsuits that were centralized in a federal Multi-District Litigation (MDL No. 2092) in the U.S. District Court for the Northern District of Alabama. In 2013, Pfizer agreed to settle about 80% of these lawsuits for $273 million. They set aside another $15 million to settle the rest. As of April 2014, only about 250 lawsuits remain unresolved in the MDL.